Deborah Fein is Board of Trustees Distinguished Professor Emeritus in the Department of Psychological Sciences and the Department of Pediatrics at the University of Connecticut in Storrs.
Deborah Fein
Board of Trustees Distinguished Professor Emeritus
University of Connecticut
From this contributor
‘Prototypical autism’ research is likely a dead end
Efforts to define “frank” or “classic” forms of the condition build on several assumptions that the science has not yet borne out.
‘Prototypical autism’ research is likely a dead end
Journal club: Why do some children lose their autism diagnosis?
More than one-third of a cohort of autistic toddlers no longer meet criteria for the condition at school age, according to a new study, but the findings may not generalize because the cohort is predominantly white and affluent.
Journal club: Why do some children lose their autism diagnosis?
Screening toddlers for autism is worthwhile
A Norwegian study published in February suggested that the Modified Checklist for Autism in Toddlers fails to detect many cases of autism at 18 months of age. The creators of the test explain why there’s more to the story.
Screening toddlers for autism is worthwhile
Explore more from The Transmitter
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
How to teach programming in the age of AI
Scientists and educators are concerned about students using artificial intelligence to shortcut their learning. But there are also opportunities, especially when it comes to teaching neuroscience students how to code.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Neuroscience conference policy draws confusion, apology
NeurIPS organizers apologized and altered course after issuing a policy that barred submissions from researchers at U.S.-government-sanctioned institutions.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.
Funding for animal research alternatives reaches ‘inflection point’
The United States and Europe are dedicating hundreds of millions of dollars in funding to advance novel alternative methods, but not all neuroscientists see this as a positive step.